Cesium toxicity - Revision history

Danbot: Strip excess bold text

2026-03-22T09:24:01Z

Strip excess bold text

Danbot: Add MedicationDose entry for magnesium sulfate

2026-03-20T21:21:20Z

Add MedicationDose entry for magnesium sulfate

@@ Line 147: / Line 147: @@
 * All intentional ingestions: psychiatric evaluation mandatory prior to discharge
 *Contact [[Poison control]] (1-800-222-1222 in the US) for all cases
 ==See Also==

Danbot: Moved intro into Background as bullets; removed excessive bold from bullet lead-ins; added Prolonged QT DDX template

2026-03-19T15:07:46Z

Moved intro into Background as bullets; removed excessive bold from bullet lead-ins; added Prolonged QT DDX template

Show changes

Ostermayer: Created page with "Cesium toxicity is an uncommon but potentially fatal poisoning caused by ingestion of cesium chloride (CsCl), most commonly as a '''complementary and alternative medicine (CAM) "cancer treatment."''' The primary danger is '''severe QTc prolongation''' with resultant ventricular tachycardia, torsades de pointes, and cardiac arrest.Sessions D, et al. Fatal Cesium Chloride Toxicity After Alternative Cancer Treatment. ''J Alte..."

2026-03-17T23:23:16Z

Created page with "Cesium toxicity is an uncommon but potentially fatal poisoning caused by ingestion of cesium chloride (CsCl), most commonly as a '''complementary and alternative medicine (CAM) "cancer treatment."''' The primary danger is '''severe QTc prolongation''' with resultant ventricular tachycardia, torsades de pointes, and cardiac arrest.<ref name="Sessions2013">Sessions D, et al. Fatal Cesium Chloride Toxicity After Alternative Cancer Treatment. ''J Alte..."

New page

Cesium toxicity is an uncommon but potentially fatal poisoning caused by ingestion of cesium chloride (CsCl), most commonly as a '''complementary and alternative medicine (CAM) "cancer treatment."''' The primary danger is '''severe QTc prolongation''' with resultant ventricular tachycardia, [[Torsades de pointes|torsades de pointes]], and cardiac arrest.<ref name="Sessions2013">Sessions D, et al. Fatal Cesium Chloride Toxicity After Alternative Cancer Treatment. ''J Altern Complement Med''. 2013;19(12):973-975. doi:10.1089/acm.2012.0731</ref>

==Background==
*Cesium (Cs) is an alkali metal in the periodic table below potassium and rubidium
*'''Cesium chloride (CsCl)''' is the form most commonly encountered in human toxicity
*Sold online and in alternative health stores as a purported cancer treatment based on '''"high pH therapy"''' — the unproven claim that alkalinizing acidic cancer cells will destroy them<ref name="Dalal2004">Dalal AK, Harding JD, Verdino RJ. Acquired long QT syndrome and monomorphic ventricular tachycardia after alternative treatment with cesium chloride for brain cancer. ''Mayo Clin Proc''. 2004;79(8):1065-1069.</ref>
*'''No controlled clinical trial has demonstrated any anticancer efficacy of CsCl'''<ref name="Sessions2013"/>
*Proponents often recommend CsCl combined with selenium, high-dose vitamins A and C, zinc, and amygdalin (laetrile)<ref name="Sessions2013"/>
*Patients frequently do not disclose CsCl use to their oncologists or emergency physicians
*Cesium is also encountered in:
**'''Radioactive form (¹³⁷Cs, ¹³⁴Cs):''' nuclear fission products; radiation exposure from nuclear accidents (managed with Prussian blue)
**'''Occupational:''' electronics manufacturing, energy production (rare significant exposure)
*'''Toxicity threshold:''' intakes of ≥6 g/day have produced severe cardiac toxicity; even lower doses (1-3 g/day) can cause QTc prolongation over weeks of use<ref name="Pinter2014">Pinter A, et al. Clinical effects of cesium intake. ''Pharmacol Res''. 2014;36(1):36-44. doi:10.1016/j.phrs.2009.06.003</ref>
*Cesium has an extremely long biological half-life (~110 days for the slow compartment), meaning toxicity '''resolves slowly''' over days to weeks after cessation<ref name="ATSDR">Toxicological Profile for Cesium. Agency for Toxic Substances and Disease Registry (ATSDR). 2004.</ref>

===Mechanism of toxicity===
*Cesium '''blocks delayed rectifier potassium channels (Iₖᵣ)''' on atrial and ventricular myocytes<ref name="Sessions2013"/>
*This prolongs '''phase 3 repolarization''' of the cardiac action potential → prolonged QT interval
*Creates substrate for '''early afterdepolarizations (EADs)''' → triggered arrhythmias
*Cesium competes with potassium for transport through potassium channels, displacing K⁺ intracellularly → causes '''hypokalemia''' and '''hypomagnesemia''', which further exacerbate QTc prolongation<ref name="Pinter2014"/>
*Hypokalemia and bradycardia synergistically increase the arrhythmogenic substrate
*Net effect: '''acquired long QT syndrome''' with high risk of [[Torsades de pointes|torsades de pointes]] and [[Ventricular tachycardia|ventricular tachycardia]]

==Clinical features==
===Mild toxicity (early or low-dose)===
*GI distress: nausea, vomiting, diarrhea, decreased appetite
*Numbness or tingling of the lips
*Fatigue, muscle weakness
*[[Hypotension]], lightheadedness

===Moderate to severe toxicity===
*'''Syncope''' (often the presenting complaint that brings patients to the ED)<ref name="Lyon2003">Lyon AW, Mayhew WJ. Cesium toxicity: a case of self-treatment by alternate therapy gone awry. ''Ther Drug Monit''. 2003;25(1):114-116.</ref>
*'''Palpitations'''
*'''Seizures'''<ref name="Dalal2004"/>

===Cardiac toxicity (the primary life-threatening feature)===
*'''"Acquired long QT syndrome":''' QTc prolongation (reported up to >700 msec)<ref name="Sessions2013"/>
*'''Polymorphic ventricular tachycardia / [[Torsades de pointes]]''' — the most dangerous manifestation
*'''Monomorphic ventricular tachycardia'''
*'''R-on-T phenomenon'''
*Premature ventricular contractions (PVCs)
*Atrial fibrillation
*'''Cardiac arrest''' (VT/VF)<ref name="Sessions2013"/>

===Electrolyte abnormalities===
*'''[[Hypokalemia]]''' — often severe; results from cesium displacing potassium<ref name="Pinter2014"/>
*'''Hypomagnesemia'''
*Both electrolyte disturbances worsen QTc prolongation and arrhythmia risk

===Timeline===
*QTc prolongation may develop over days to weeks of oral CsCl use
*Cardiac arrhythmias may occur suddenly without warning
*After cessation, QTc prolongation resolves slowly ('''days to weeks''') due to cesium's long half-life<ref name="Dalal2004"/>

==Differential diagnosis==
===Acquired [[Long QT syndrome]] (other causes)===
*Drug-induced QTc prolongation (antiarrhythmics, antipsychotics, fluoroquinolones, antiemetics, methadone)
*[[Hypokalemia]] (other causes)
*[[Hypomagnesemia]] (other causes)
*[[Hypocalcemia]]
*Hypothermia
*Myocardial ischemia

===Other causes of syncope with arrhythmia===
*[[Brugada syndrome]]
*Congenital [[Long QT syndrome]]
*[[Hypertrophic cardiomyopathy]]
*[[Wolff-Parkinson-White syndrome]]

===Other supplement/CAM toxicities===
*[[Arsenic poisoning]] (found in some traditional remedies)
*Laetrile/amygdalin toxicity ([[Cyanide poisoning]])
*Selenium toxicity

==Evaluation==
===Workup===
*'''Detailed history of supplement/CAM use''' — ''the single most important diagnostic step''
**Patients often do not volunteer CsCl use; ask specifically about alternative cancer treatments, supplements, "high pH therapy," "alkalinization therapy"
**Ask about concurrent supplement use (selenium, laetrile, high-dose vitamins)
*'''12-lead ECG:''' QTc measurement is critical<ref name="Sessions2013"/>
**QTc >500 msec is high-risk for torsades de pointes
**Reported QTc values in cesium toxicity: 546-735 msec
**Look for PVCs, R-on-T phenomenon, VT
*'''Continuous cardiac monitoring''' on telemetry
*'''Electrolytes:''' potassium, magnesium, calcium (expect hypokalemia and hypomagnesemia)
*'''BMP:''' renal function
*'''Troponin:''' usually negative (no structural heart disease); helps exclude ACS
*'''Echocardiography:''' typically normal ventricular function; excludes structural causes
*'''Cesium levels:'''
**Whole blood cesium level (reference range <10 μg/L); levels >10,000 μg/L have been associated with fatal outcomes<ref name="Sessions2013"/>
**Plasma cesium level (reference range <10 μg/L)
**Urine cesium level
**Levels confirm diagnosis but do '''not''' reliably correlate with QTc duration or arrhythmia severity
**Treatment should '''not''' be delayed pending levels

===Diagnosis===
*Clinical: history of CsCl supplement use + QTc prolongation + hypokalemia ± arrhythmia
*High index of suspicion needed in any cancer patient presenting with syncope, palpitations, or new arrhythmia — ask about CAM use
*Cesium toxicity should be included in the differential diagnosis of '''unexplained acquired long QT syndrome'''<ref name="Lyon2003"/>

==Management==
===Immediate===
*'''Stop cesium chloride immediately'''
*'''Continuous cardiac monitoring''' — high risk of VT/torsades
*'''IV access; resuscitation equipment at bedside'''

===Electrolyte repletion===
*'''Aggressive IV potassium repletion''' — target high-normal serum K⁺ (4.5-5.0 mEq/L) to counteract cesium's potassium-displacing effect
**Cesium-associated hypokalemia may be refractory to standard repletion; '''amiloride''' (a potassium-sparing diuretic that blocks the distal tubular sodium channel through which cesium enters) has been used successfully as adjunctive therapy<ref name="Horn2015">Horn S, Naidus E, Alper SL, Danziger J. Cesium-associated hypokalemia successfully treated with amiloride. ''Clin Kidney J''. 2015;8(3):335-338. doi:10.1093/ckj/sfv017</ref>
*'''IV magnesium sulfate''' — replete aggressively; magnesium is also first-line treatment for torsades de pointes
*Monitor electrolytes frequently (at least q4-6h initially)

===Arrhythmia management===
*'''Torsades de pointes:'''
**'''IV magnesium sulfate''' 2 g IV bolus (first-line)
**'''Overdrive pacing''' (transvenous or transcutaneous) — increases heart rate to shorten QT interval and suppress EADs<ref name="Dalal2004"/>
**'''Isoproterenol''' infusion — temporizing measure to increase heart rate if pacing unavailable
**'''Electrical cardioversion/defibrillation''' for hemodynamically unstable VT/VF
*'''Monomorphic VT:'''
**'''IV lidocaine''' — reported effective in cesium-induced VT<ref name="Dalal2004"/>
*'''Avoid class IA (procainamide, quinidine), class IC, and class III (amiodarone, sotalol) antiarrhythmics''' — all prolong QTc and will worsen the arrhythmogenic substrate<ref name="Sessions2013"/>
*'''Avoid other QTc-prolonging medications''' (ondansetron, droperidol, haloperidol, fluoroquinolones, etc.)

===Enhanced elimination===
*'''Prussian blue (ferric hexacyanoferrate):''' 1 g PO three times daily<ref name="Sessions2013"/>
**Binds cesium in the GI lumen via ion exchange, preventing reabsorption and enhancing fecal excretion
**FDA-approved for treatment of radioactive cesium (¹³⁷Cs) contamination; has been used off-label for stable cesium (CsCl) toxicity
**Reduces biological half-life of cesium to approximately one-third of normal<ref name="ATSDR"/>
**Available through the Radiation Emergency Assistance Center/Training Site (REAC/TS) or Strategic National Stockpile
*'''Hemodialysis:''' cesium is dialyzable given its low molecular weight and distribution similar to potassium; may be considered in severe life-threatening toxicity, though clinical data are limited
*Note: even with treatment, QTc prolongation may take '''days to weeks''' to resolve due to cesium's long tissue half-life

===Supportive care===
*Seizure management: [[Benzodiazepines|benzodiazepines]] first-line
*Hemodynamic support as needed

==Disposition==
*'''All patients with QTc prolongation from cesium:''' admit to ICU or cardiac-monitored setting
*'''Continuous telemetry''' until QTc consistently <500 msec and no arrhythmias for 24-48 hours
*Serial ECGs and electrolytes q4-6h initially, then q12h as QTc improves
*QTc may remain prolonged for '''days to weeks''' — do not discharge prematurely
*'''Cessation of CsCl is mandatory''' — counsel patient and family clearly that CsCl has no proven anticancer benefit and is life-threatening
*Consider ongoing Prussian blue therapy if available
*Follow-up with cardiology and oncology
*'''All intentional ingestions:''' psychiatric evaluation mandatory prior to discharge
*Contact [[Poison control]] (1-800-222-1222 in the US) for all cases

==See Also==
*[[Long QT syndrome]]
*[[Torsades de pointes]]
*[[Ventricular tachycardia]]
*[[Hypokalemia]]
*[[Hypomagnesemia]]
*[[Drug-induced QTc prolongation]]

==External Links==
*[https://pmc.ncbi.nlm.nih.gov/articles/PMC3868249/ J Altern Complement Med — Fatal Cesium Chloride Toxicity After Alternative Cancer Treatment (2013)]
*[https://www.ncbi.nlm.nih.gov/books/NBK594667/ ATSDR — Toxicological Profile for Cesium: Health Effects]
*[https://pubmed.ncbi.nlm.nih.gov/19655100/ Pharmacol Res — Clinical effects of cesium intake (2009)]
*[https://pubmed.ncbi.nlm.nih.gov/12548155/ Ther Drug Monit — Cesium Toxicity: A Case of Self-Treatment by Alternate Therapy Gone Awry (2003)]
*[https://pubmed.ncbi.nlm.nih.gov/15301336/ Mayo Clin Proc — Acquired long QT syndrome and monomorphic VT after alternative treatment with CsCl (2004)]

==References==
<references/>

[[Category:Toxicology]]
[[Category:Cardiology]]

← Older revision		Revision as of 09:24, 22 March 2026
Line 3:		Line 3:
	*Cesium (Cs) is an alkali metal in the periodic table below potassium and rubidium		*Cesium (Cs) is an alkali metal in the periodic table below potassium and rubidium
	* Cesium chloride (CsCl) is the form most commonly encountered in human toxicity		* Cesium chloride (CsCl) is the form most commonly encountered in human toxicity
	*Sold online and in alternative health stores as a purported cancer treatment based on ~~'''~~"high pH therapy"~~'''~~ — the unproven claim that alkalinizing acidic cancer cells will destroy them<ref name="Dalal2004">Dalal AK, Harding JD, Verdino RJ. Acquired long QT syndrome and monomorphic ventricular tachycardia after alternative treatment with cesium chloride for brain cancer. ''Mayo Clin Proc''. 2004;79(8):1065-1069.</ref>		*Sold online and in alternative health stores as a purported cancer treatment based on "high pH therapy" — the unproven claim that alkalinizing acidic cancer cells will destroy them<ref name="Dalal2004">Dalal AK, Harding JD, Verdino RJ. Acquired long QT syndrome and monomorphic ventricular tachycardia after alternative treatment with cesium chloride for brain cancer. ''Mayo Clin Proc''. 2004;79(8):1065-1069.</ref>
	* No controlled clinical trial has demonstrated any anticancer efficacy of CsCl<ref name="Sessions2013"/>		* No controlled clinical trial has demonstrated any anticancer efficacy of CsCl<ref name="Sessions2013"/>
	*Proponents often recommend CsCl combined with selenium, high-dose vitamins A and C, zinc, and amygdalin (laetrile)<ref name="Sessions2013"/>		*Proponents often recommend CsCl combined with selenium, high-dose vitamins A and C, zinc, and amygdalin (laetrile)<ref name="Sessions2013"/>
Line 11:		Line 11:
	** Occupational: electronics manufacturing, energy production (rare significant exposure)		** Occupational: electronics manufacturing, energy production (rare significant exposure)
	* Toxicity threshold: intakes of ≥6 g/day have produced severe cardiac toxicity; even lower doses (1-3 g/day) can cause QTc prolongation over weeks of use<ref name="Pinter2014">Pinter A, et al. Clinical effects of cesium intake. ''Pharmacol Res''. 2014;36(1):36-44. doi:10.1016/j.phrs.2009.06.003</ref>		* Toxicity threshold: intakes of ≥6 g/day have produced severe cardiac toxicity; even lower doses (1-3 g/day) can cause QTc prolongation over weeks of use<ref name="Pinter2014">Pinter A, et al. Clinical effects of cesium intake. ''Pharmacol Res''. 2014;36(1):36-44. doi:10.1016/j.phrs.2009.06.003</ref>
	*Cesium has an extremely long biological half-life (~110 days for the slow compartment), meaning toxicity ~~'''~~resolves slowly~~'''~~ over days to weeks after cessation<ref name="ATSDR">Toxicological Profile for Cesium. Agency for Toxic Substances and Disease Registry (ATSDR). 2004.</ref>		*Cesium has an extremely long biological half-life (~110 days for the slow compartment), meaning toxicity resolves slowly over days to weeks after cessation<ref name="ATSDR">Toxicological Profile for Cesium. Agency for Toxic Substances and Disease Registry (ATSDR). 2004.</ref>

	===Mechanism of toxicity===		===Mechanism of toxicity===
	*Cesium ~~'''~~blocks delayed rectifier potassium channels (Iₖᵣ)~~'''~~ on atrial and ventricular myocytes<ref name="Sessions2013"/>		*Cesium blocks delayed rectifier potassium channels (Iₖᵣ) on atrial and ventricular myocytes<ref name="Sessions2013"/>
	*This prolongs ~~'''~~phase 3 repolarization~~'''~~ of the cardiac action potential → prolonged QT interval		*This prolongs phase 3 repolarization of the cardiac action potential → prolonged QT interval
	*Creates substrate for ~~'''~~early afterdepolarizations (EADs)~~'''~~ → triggered arrhythmias		*Creates substrate for early afterdepolarizations (EADs) → triggered arrhythmias
	*Cesium competes with potassium for transport through potassium channels, displacing K⁺ intracellularly → causes ~~'''~~hypokalemia~~'''~~ and ~~'''~~hypomagnesemia~~'''~~, which further exacerbate QTc prolongation<ref name="Pinter2014"/>		*Cesium competes with potassium for transport through potassium channels, displacing K⁺ intracellularly → causes hypokalemia and hypomagnesemia, which further exacerbate QTc prolongation<ref name="Pinter2014"/>
	*Hypokalemia and bradycardia synergistically increase the arrhythmogenic substrate		*Hypokalemia and bradycardia synergistically increase the arrhythmogenic substrate
	*Net effect: ~~'''~~acquired long QT syndrome~~'''~~ with high risk of [[Torsades de pointes\|torsades de pointes]] and [[Ventricular tachycardia\|ventricular tachycardia]]		*Net effect: acquired long QT syndrome with high risk of [[Torsades de pointes\|torsades de pointes]] and [[Ventricular tachycardia\|ventricular tachycardia]]

	==Clinical features==		==Clinical features==
Line 50:		Line 50:
	*QTc prolongation may develop over days to weeks of oral CsCl use		*QTc prolongation may develop over days to weeks of oral CsCl use
	*Cardiac arrhythmias may occur suddenly without warning		*Cardiac arrhythmias may occur suddenly without warning
	*After cessation, QTc prolongation resolves slowly (~~'''~~days to weeks~~'''~~) due to cesium's long half-life<ref name="Dalal2004"/>		*After cessation, QTc prolongation resolves slowly (days to weeks) due to cesium's long half-life<ref name="Dalal2004"/>

	==Differential diagnosis==		==Differential diagnosis==
Line 93:		Line 93:
	**Plasma cesium level (reference range <10 μg/L)		**Plasma cesium level (reference range <10 μg/L)
	**Urine cesium level		**Urine cesium level
	**Levels confirm diagnosis but do ~~'''~~not~~'''~~ reliably correlate with QTc duration or arrhythmia severity		**Levels confirm diagnosis but do not reliably correlate with QTc duration or arrhythmia severity
	**Treatment should ~~'''~~not~~'''~~ be delayed pending levels		**Treatment should not be delayed pending levels

	===Diagnosis===		===Diagnosis===
	*Clinical: history of CsCl supplement use + QTc prolongation + hypokalemia ± arrhythmia		*Clinical: history of CsCl supplement use + QTc prolongation + hypokalemia ± arrhythmia
	*High index of suspicion needed in any cancer patient presenting with syncope, palpitations, or new arrhythmia — ask about CAM use		*High index of suspicion needed in any cancer patient presenting with syncope, palpitations, or new arrhythmia — ask about CAM use
	*Cesium toxicity should be included in the differential diagnosis of ~~'''~~unexplained acquired long QT syndrome~~'''~~<ref name="Lyon2003"/>		*Cesium toxicity should be included in the differential diagnosis of unexplained acquired long QT syndrome<ref name="Lyon2003"/>

	==Management==		==Management==
Line 109:		Line 109:
	===Electrolyte repletion===		===Electrolyte repletion===
	* Aggressive IV potassium repletion — target high-normal serum K⁺ (4.5-5.0 mEq/L) to counteract cesium's potassium-displacing effect		* Aggressive IV potassium repletion — target high-normal serum K⁺ (4.5-5.0 mEq/L) to counteract cesium's potassium-displacing effect
	**Cesium-associated hypokalemia may be refractory to standard repletion; ~~'''~~amiloride~~'''~~ (a potassium-sparing diuretic that blocks the distal tubular sodium channel through which cesium enters) has been used successfully as adjunctive therapy<ref name="Horn2015">Horn S, Naidus E, Alper SL, Danziger J. Cesium-associated hypokalemia successfully treated with amiloride. ''Clin Kidney J''. 2015;8(3):335-338. doi:10.1093/ckj/sfv017</ref>		**Cesium-associated hypokalemia may be refractory to standard repletion; amiloride (a potassium-sparing diuretic that blocks the distal tubular sodium channel through which cesium enters) has been used successfully as adjunctive therapy<ref name="Horn2015">Horn S, Naidus E, Alper SL, Danziger J. Cesium-associated hypokalemia successfully treated with amiloride. ''Clin Kidney J''. 2015;8(3):335-338. doi:10.1093/ckj/sfv017</ref>
	* IV magnesium sulfate — replete aggressively; magnesium is also first-line treatment for torsades de pointes		* IV magnesium sulfate — replete aggressively; magnesium is also first-line treatment for torsades de pointes
	*Monitor electrolytes frequently (at least q4-6h initially)		*Monitor electrolytes frequently (at least q4-6h initially)
Line 131:		Line 131:
	**Available through the Radiation Emergency Assistance Center/Training Site (REAC/TS) or Strategic National Stockpile		**Available through the Radiation Emergency Assistance Center/Training Site (REAC/TS) or Strategic National Stockpile
	* Hemodialysis: cesium is dialyzable given its low molecular weight and distribution similar to potassium; may be considered in severe life-threatening toxicity, though clinical data are limited		* Hemodialysis: cesium is dialyzable given its low molecular weight and distribution similar to potassium; may be considered in severe life-threatening toxicity, though clinical data are limited
	*Note: even with treatment, QTc prolongation may take ~~'''~~days to weeks~~'''~~ to resolve due to cesium's long tissue half-life		*Note: even with treatment, QTc prolongation may take days to weeks to resolve due to cesium's long tissue half-life

	===Supportive care===		===Supportive care===